Related Experiment Video
Updated: Jul 7, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Guillain-Barré syndrome after treatment with sunitinib malate?
Brian Mulherin1, Noelle K Loconte, Kyle D Holen
1Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center, Madison, USA.
Abstract:
Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor used for treatment of renal cell carcinoma and gastrointestinal stromal tumor. We report a case of a patient who developed Guillain-Barrd syndrome after initial treatment with sunitinib, with recurrent symptoms upon reintroducing the drug. This is the first report of such an effect. The literature on chemotherapy-induced Guillain-Barri syndrome is also reviewed. Oncology providers should be aware of this rare but potentially serious possible adverse effect of sunitinib.
Insights
Sunitinib, a cancer drug, can cause Guillain-Barré syndrome, a rare neurological disorder. This case study highlights the risk of recurrent symptoms upon reintroducing sunitinib, urging oncologist awareness.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- Sunitinib malate (Sutent) is an oral multitargeted tyrosine kinase inhibitor.
- It is approved for treating renal cell carcinoma and gastrointestinal stromal tumor.
Purpose of the Study:
- To report a case of Guillain-Barré syndrome (GBS) following sunitinib treatment.
- To review the literature on chemotherapy-induced GBS.
- To raise awareness among oncology providers about this potential adverse effect.
Main Methods:
- Case report of a patient who developed GBS after sunitinib initiation.
- Recurrence of GBS symptoms upon sunitinib reintroduction.
- Literature review of chemotherapy-induced GBS.
Main Results:
- The patient developed GBS after starting sunitinib.
- GBS symptoms recurred when sunitinib was reintroduced.
- This is the first reported case of sunitinib-induced GBS with recurrence.
Conclusions:
- Sunitinib may cause Guillain-Barré syndrome.
- Recurrent GBS is possible with sunitinib reintroduction.
- Oncology providers should consider GBS as a rare but serious adverse effect of sunitinib.
